NCT04871035 Immunoadsorption Versus Plasma Exchange for Treatment of Guillain-Barré Syndrome (GBS)
| NCT ID | NCT04871035 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Ulm |
| Condition | GBS |
| Study Type | OBSERVATIONAL |
| Enrollment | 20 participants |
| Start Date | 2021-04-28 |
| Primary Completion | 2027-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20 participants in total. It began in 2021-04-28 with a primary completion date of 2027-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an observations study evaluating safety and efficacy of immunoadsorption compared to plasma exchange in Guillain-Barré Syndrome.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of Guillain-Barré Syndrome according to the diagnostic criteria proposed by Doorn et al. (Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome, Lancet neurology 2008) * age 18 years or above Exclusion Criteria: * Clinical or laboratory (C-reactive protein 20 mg/l or above, or evidence of nitrite-positive urinary tract infection) evidence of manifest systemic infection * Intake of angiotensin converting enzyme inhibitor within1 weeks before first treatment * Other contraindications against immunoadsorption or plasma exchange
Contact & Investigator
Johannes Dorst, Prof
PRINCIPAL INVESTIGATOR
University of Ulm
Frequently Asked Questions
Who can join the NCT04871035 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying GBS. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04871035 currently recruiting?
Yes, NCT04871035 is actively recruiting participants. Contact the research team at johannes.dorst@uni-ulm.de for enrollment information.
Where is the NCT04871035 trial being conducted?
This trial is being conducted at Ulm, Germany.
Who is sponsoring the NCT04871035 clinical trial?
NCT04871035 is sponsored by University of Ulm. The principal investigator is Johannes Dorst, Prof at University of Ulm. The trial plans to enroll 20 participants.